Clinical Scorecard: Metabolic Intersections: The Role of Glycolysis in Cancer and Neurodegenerative Disorders

At a Glance

Key Highlights

• Cancer survivors show lower rates of neurodegeneration.
• Aerobic glycolysis is critical for cancer cell proliferation and offers neuroprotection in the brain.
• ACAA2 gene expression is inversely regulated in cancer and neurodegenerative diseases.
• Metabolic reprogramming may serve as a therapeutic target for both conditions.
• Age-related metabolic dysregulation may underlie both sporadic cancer and neurodegenerative diseases.

Guideline-Based Recommendations

Diagnosis

• Utilize RNA sequencing data for identifying altered glycolysis-related genes in cancer and neurodegenerative diseases.

Management

• Consider restoring astrocytic glycolysis and lactate production as a therapeutic strategy for neurodegenerative diseases.

Monitoring & Follow-up

• Monitor gene expression patterns of glycolysis-related genes in patients with cancer and neurodegenerative diseases.

Risks

• Increased susceptibility to neurodegeneration may be linked to a decline in aerobic glycolysis.

Patient & Prescribing Data

Patients with colon adenocarcinoma and neurodegenerative diseases.

Targeting metabolic pathways may provide new treatment options for both cancer and neurodegenerative conditions.

Clinical Best Practices

• Integrate metabolic profiling in the assessment of cancer and neurodegenerative diseases.
• Utilize public databases for comparative analysis of gene expression in research.

References

• TCGA Database
• GEO Database